Clinical trials in Tallin – page 9

148 clinical trials in Tallin, Estonia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in EstoniaKliinilisedUuringud.ee

Tallin at a glance

148

clinical trials

Research sites1

Quick filters

148 trials in Tallin

Open in trial search

Emphysema

Not recruiting

Study on Long-term Safety of Weekly Intravenous Alpha-1-Proteinase Inhibitor for Patients with Pulmonary Emphysema Due to Alpha-1-Antitrypsin Deficiency

Registered drugNo placebo

Study on Long-term Safety of Weekly Intravenous Alpha-1-Proteinase Inhibitor for Patients with Pulmonary Emphysema Due to Alpha-1-Antitrypsin Deficiency

Registered drugNo placebo

Estonia

Participants:18–64 years · 65+ years
Substances:ALPHA-1-PROTEINASE inhibitor (human)
Sponsor:Grifols Therapeutics LLC

Contact Research Centre

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Sparsentan and Dapagliflozin for Patients with Immunoglobulin A Nephropathy (IgAN)

Registered drugNo placebo

Study on the Effectiveness and Safety of Sparsentan and Dapagliflozin for Patients with Immunoglobulin A Nephropathy (IgAN)

Registered drugNo placebo

Estonia

Participants:18–64 years · 65+ years
Substances:Dapagliflozin
Sponsor:Travere Therapeutics Inc.

Contact Research Centre

Neovascular age-related macular degeneration

Not recruiting

Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drug

Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drug

Estonia

Participants:18–64 years · 65+ years
Substances:Aflibercept
Sponsor:Opthea Limited

Contact Research Centre

Urinary tract infection+1

Not recruiting

Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis

Registered drugNo placebo

Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis

Registered drugNo placebo

Estonia

Participants:18–64 years · 65+ years
Substances:Aztreonam
Sponsor:Meiji Seika Pharma Co. Ltd.

Contact Research Centre

Influenza

Not recruiting

Study of mRNA-1010 Influenza Vaccine Compared to Standard Flu Vaccine in Adults 50 Years and Older

Registered drugNo placebo

Study of mRNA-1010 Influenza Vaccine Compared to Standard Flu Vaccine in Adults 50 Years and Older

Registered drugNo placebo

Estonia

Participants:18–64 years · 65+ years
Substances:CX-037231
Sponsor:Moderna Inc.

Contact Research Centre

Interstitial lung disease

Not recruiting

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational

Estonia

Participants:65+ years
Substances:BI 1015550
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Colitis ulcerative

Not recruiting

Study on Long-Term Safety of Etrasimod Arginine for Patients with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo

Study on Long-Term Safety of Etrasimod Arginine for Patients with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo

Estonia

Participants:0–17 years · 18–64 years · 65+ years
Substances:Etrasimod Arginine
Sponsor:Arena Pharmaceuticals Inc.

Contact Research Centre

Focal segmental glomerulosclerosis

Not recruiting

Study on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

Registered drugNo placebo

Study on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

Registered drugNo placebo

Estonia

Participants:0–17 years · 18–64 years · 65+ years
Substances:Irbesartan
Sponsor:Travere Therapeutics Inc.

Contact Research Centre

Major depression

Not recruiting

Study on the Effects of BH-200 (Nelivaptan) for Patients with Major Depressive Disorder

Investigational

Study on the Effects of BH-200 (Nelivaptan) for Patients with Major Depressive Disorder

Investigational

Estonia

Participants:18–64 years · 65+ years
Substances:Nelivaptan
Sponsor:HMNC Holding GmbH

Contact Research Centre

Relapsing multiple sclerosis

Not recruiting

Study on the Effects of Vidofludimus Calcium in Adults with Relapsing Multiple Sclerosis

Investigational

Study on the Effects of Vidofludimus Calcium in Adults with Relapsing Multiple Sclerosis

Investigational

Estonia

Participants:18–64 years
Substances:Vidofludimus Calcium
Sponsor:Immunic AG

Contact Research Centre

Gastric cancer+1

Not recruiting

Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

Registered drugNo placebo

Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

Registered drugNo placebo

Estonia

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Jazz Pharmaceuticals Ireland Limited

Contact Research Centre

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Registered drug

Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Registered drug

Estonia

Participants:0–17 years
Substances:Dimenhydrinate
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Other cities in Estonia

The busiest research cities in the country

All 11 cities in Estonia

Clinical research in Tallin

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on innovative treatments for ulcerative colitis, specifically targeting patients with mild to moderate left-sided manifestations of the condition. The research explores new therapeutic approaches using targeted delivery methods.

Inflammatory Bowel Disease Management
Novel Drug Delivery Systems
Gastrointestinal Therapeutics

These trials aim to evaluate the effectiveness of a new localized treatment approach compared to placebo, potentially offering improved options for patients with inflammatory bowel conditions.

Back to Estonia All countries